Breakthrough Breast Cancer supports a ‘bench to bedside’ approach, seeking to translate research findings as quickly as possible into the clinical setting. So far, Breakthrough’s work has led to five clinical trials, four of which directly build on research that took place in Breakthrough’s laboratories.


  • BRCA Trial
    Phase II trial investigating carboplatin as the first-ever chemotherapy treatment designed specifically for women with BRCA associated breast cancer.


  • PARP Inhibitor Trials
    Two Phase II trials investigating PARP inhibitors as the first targeted treatment for women with BRCA-associated breast and ovarian cancer.


  • TNT trial
    The Triple Negative Trial aims to develop a more tailored and effective chemotherapy treatment for women with hormone and HER2 receptor negative breast cancer, which has spread elsewhere in the body.


  • ACU.FATIGUE
    The world’s largest and most advanced clinical trial to investigate whether acupuncture may help women with cope with breast cancer-related fatigue.


    • If you are a cancer patient looking for information on these trials, you may wish to look at the CancerHelp UK website.